Welcome to our dedicated page for Collplant Biotechnologies SEC filings (Ticker: CLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CollPlant Biotechnologies Ltd (NASDAQ: CLGN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. CollPlant files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These documents include press releases on financial results, product development updates, distribution agreements, corporate governance matters and interim financial statements.
Through its Form 6-K submissions, CollPlant furnishes materials such as quarterly financial results, condensed consolidated interim financial statements, operating and financial reviews, and detailed press releases on topics like expansion of rhCollagen distribution capabilities in North America, positive non-clinical data for its photocurable dermal and soft tissue filler, and distribution expansion for its Vergenix STR tendon-repair product in Europe. Filings also cover announcements related to scientific collaborations, including studies involving its Collink.3D rhCollagen-based bioink and Mayo Clinic’s fully humanized 3D bioprinted skin model, as well as notices of shareholder meetings and proxy materials.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand financial performance, progress in regenerative and aesthetic medicine programs, and material agreements such as CollPlant’s development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company. Real-time updates from EDGAR ensure that new 6-K and 20-F reports are available promptly.
Users can review CollPlant’s historical and current filings to analyze trends in its rhCollagen-based business, monitor disclosures about collaborations and product pipelines, and better understand the regulatory context of its 3D bioprinting, tissue repair and medical aesthetics activities.
CollPlant Biotechnologies reported that the Korean Patent Office has allowed a patent application covering key aspects of its photocurable dermal filler technology, which is based on the company’s recombinant human collagen (rhCollagen) platform and is currently under development for the aesthetic market.
The patent covers a polymerizable rhCollagen-based solution, combined with components such as a hyaluronic acid filler, injected into sub‑epidermal tissue and polymerized in situ using external light activation to form a supportive scaffold for tissue augmentation and contour stability. Patent protection is expected to extend through 2039.
The company notes that this Korean allowance follows a recently granted Japanese patent for related photocurable dermal filler compositions and adds to existing patent protection in the United States, Europe, China, Brazil, Australia, and Israel. CollPlant highlights that this technology targets the global injectable soft‑tissue filler market, which it cites as exceeding $6 billion.
CollPlant Biotechnologies Ltd. filed a Form 6-K to announce the launch of BioFlex, a ready-to-print bioink kit based on its recombinant human collagen (rhCollagen) platform for Digital Light Processing 3D bioprinting.
BioFlex combines rhCollagen, a biodegradable polymer (Collink.3D™ 50), and proprietary photoactive agents to help academic and industry users rapidly formulate customized bioinks. The kit is designed to streamline development of advanced tissue models, engineered tissues, and transplantable organ scaffolds by improving mechanical performance and printability in tissue engineering and regenerative medicine applications.
CollPlant Biotechnologies Ltd. filed a Form 6-K highlighting a strategic move to target a new aesthetic market emerging from GLP-1 weight-loss treatments. The company is developing a next-generation, photocurable dermal filler based on its recombinant human collagen (rhCollagen) to address facial volume loss linked to rapid weight reduction.
The filler is designed to restore facial structure immediately, form a light-activated, crosslinked scaffold, and support tissue integration and potential long-term skin quality improvements. The technology is currently in the preclinical stage and is part of CollPlant’s broader regenerative aesthetics strategy, which also includes age-related volume loss, skin regeneration, and structural soft tissue restoration.
CollPlant Biotechnologies Ltd. entered into a securities purchase agreement for a registered direct offering of 1,600,000 ordinary shares at
The series A and B warrants have an exercise price of
CollPlant will pay H.C. Wainwright & Co. a 7% placement fee, 1% management fee, and fixed expenses, and issue placement agent warrants equal to 6% of the shares sold, or warrants for 96,000 ordinary shares at an exercise price of
CollPlant Biotechnologies Ltd. is raising equity capital through a primary offering of 1,600,000 ordinary shares at $1.25 per share, for gross proceeds of $2.0 million and estimated net proceeds of about $1.7 million. After placement fees and expenses, the company expects to receive approximately $1.86 million before expenses and plans to use the funds for general corporate purposes, including working capital and research and development.
Following the offering, ordinary shares outstanding are expected to increase from 12,803,006 to 14,403,006, implying immediate dilution for new investors, with as-adjusted net tangible book value rising to $0.76 per share versus a $1.25 purchase price. In a concurrent private placement, investors will receive unregistered Series A and Series B warrants to purchase up to 3,200,000 additional ordinary shares at $1.25 per share, which could lead to further dilution if exercised.
The company notes that current cash resources, including expected net proceeds from this offering, are not sufficient to fund operations for the next 12 months, and its ability to continue as a going concern depends on securing additional financing or milestone payments under its AbbVie development agreement. CollPlant recently achieved a $2 million development milestone with AbbVie and remains focused on rhCollagen-based regenerative and aesthetic products, while operating under reduced reporting requirements as a foreign private issuer listed on Nasdaq under the symbol “CLGN”.
CollPlant Biotechnologies is raising new capital through a registered direct offering of 1,600,000 ordinary shares at
In a concurrent private placement, CollPlant will issue unregistered series A warrants to purchase up to 1,600,000 ordinary shares and series B warrants to purchase up to 1,600,000 ordinary shares, each with an exercise price of
CollPlant Biotechnologies Ltd. reported that it will hold an annual and extraordinary general meeting of shareholders on December 31, 2025, at 10:00 a.m. Israel time. The meeting will take place at the offices of Goldfarb Gross Seligman & Co. in the Azrieli Center in Tel-Aviv, Israel.
To support this meeting, CollPlant is providing a notice and proxy statement and a proxy card for holders of ordinary shares. The report is also incorporated by reference into several of the company’s existing Form S-8 and Form F-3 registration statements, meaning those registration statements will now include this information as part of their disclosure record.
CollPlant Biotechnologies filed a Form 6-K reporting it issued a press release titled “CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada.” The release is furnished as an exhibit to the report. The update highlights broader distribution coverage for the company’s rhCollagen across the U.S. and Canada.